Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS study (protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome)

Journal of the American College of Cardiology

Volumn 63, Issue 1, 2014, Pages 71-79

  Leoncini, Mario ^a   Toso, Anna ^a   Maioli, Mauro ^a   Tropeano, Francesco ^a   Villani, Simona ^b   Bellandi, Francesco ^a  

^a Prato Hospital   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

acute coronary syndrome(s); contrast induced nephropathy; statins

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CLOPIDOGREL; CONTRAST MEDIUM; HEPARIN; ROSUVASTATIN; CREATININE; IODIXANOL;

ACUTE CORONARY SYNDROME; ACUTE KIDNEY FAILURE; AGED; ANGIOGRAPHY; ARTICLE; BYPASS SURGERY; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEATH; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEART INFARCTION; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; KIDNEY INJURY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TRANSLUMINAL CORONARY ANGIOPLASTY; CREATININE CLEARANCE; EARLY INTERVENTION; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMOFILTRATION; INCIDENCE; LENGTH OF STAY; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; OPEN STUDY; OUTCOME ASSESSMENT; SHORT COURSE THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

3-HYDROXYL-3-METHYLGLUTARYL COENZYME A; ACS; ACUTE CORONARY SYNDROME(S); CI-AKI; CONTRAST-INDUCED ACUTE KIDNEY INJURY; CONTRAST-INDUCED NEPHROPATHY; ECRCL; EGFR; ESTIMATED CREATININE CLEARANCE; ESTIMATED GLOMERULAR FILTRATION RATE; HMG-COA; LEFT VENTRICULAR EJECTION FRACTION; LVEF; N-ACETYLCYSTEINE; NAC; NSTE; PCI; PERCUTANEOUS CORONARY INTERVENTION; STATINS; WITHOUT ST-SEGMENT ELEVATION;

ACUTE CORONARY SYNDROME; ACUTE KIDNEY INJURY; AGED; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FLUOROBENZENES; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; PYRIMIDINES; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84891805544     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.04.105     Document Type: Article

References (40)

1. P.A. McCullough Contrast-induced acute kidney injury J Am Coll Cardiol 51 2008 1419 1428
2. M.T. James, W.A. Ghali, M.L. Knudtson Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators Associations between acute kidney injury and cardiovascular and renal outcomes after coronary angiography Circulation 123 2011 409 416
3. M. Maioli, A. Toso, M. Leoncini, M. Gallopin, N. Musilli, and F. Bellandi Persistent renal damage after contrast-induced acute kidney injury: incidence, evolution, risk factors, and prognosis Circulation 125 2012 3099 3107
4. P.A. McCullough, A. Adam, C.R. Becker CIN Consensus Working Panel Epidemiology and prognostic implications of contrast-induced nephropathy Am J Cardiol 98 2006 5K 13K
5. R. Mehran, E.D. Aymong, and E. Nikolsky et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention J Am Coll Cardiol 44 2004 1393 1399
6. S.S. Brar, A. Yuh-Jer Shen, and M.B. Jorgensen et al. Sodium bicarbonate versus sodium chloride for the prevention of contrast media-induced nephropathy in patients undergoing coronary angiography JAMA 300 2008 1038 1046
7. T. Senoo, M. Motohiro, and H. Kamihata et al. Contrast-induced nephropathy in patients undergoing emergency percutaneous coronary intervention for acute coronary syndrome Am J Cardiol 105 2010 624 628
8. ACT Investigators Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT) Circulation 124 2011 1250 1259
9. G. Marenzi, C. Ferrari, and I. Marana et al. Prevention of contrast nephropathy by furosemide with matched hydration: the MYTHOS (Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy Prevention) trial J Am Coll Cardiol Intv 5 2012 90 97
10. F. Stacul, A.J. van der Molen, P. Reimer Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR) Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines Eur Radiol 21 2011 2527 2541
11. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Association for Percutaneous Cardiovascular Interventions (EAPCI). Guidelines on myocardial revascularization Eur Heart J 31 2010 2501 2555
12. G.N. Levine, E.R. Bates, and J.C. Blankenship et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions J Am Coll Cardiol 58 2011 e44 122
13. S.H. Jo, B.K. Koo, and J.S. Park et al. Prevention of radiocontrast-media-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial-a randomized controlled study Am Heart J 155 2008 499e1 499e8
14. A. Toso, M. Maioli, and M. Leoncini et al. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease Am J Cardiol 105 2010 288 292
15. J. Xinwei, F. Xianghua, and Z. Jing et al. Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention Am J Cardiol 104 2009 519 524
16. G. Patti, E. Ricottini, and A. Nusca et al. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN (atorvastatin for reduction of myocardial damage during angioplasty-contrast-induced nephropathy) trial) Am J Cardiol 108 2011 1 7
17. H. Ozhan, I. Erden, and S. Ordu et al. Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography Angiology 61 2010 711 714
18. C. Quintavalle, D. Fiore, and F. De Micco et al. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury Circulation 126 2012 3008 3016
19. R. Pappy, S. Stavrakis, T.A. Hennebry, and M.S. Abu-Fadel Effect of statin therapy on contrast-induced nephropathy after coronary angiography: a meta-analysis Int J Cardiol 151 2011 348 353
20. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
21. A.S. Levey, J.P. Bosch, J.B. Lewis, T. Greene, N. Rogers, and D. Roth A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group Ann Intern Med 130 1999 461 470
22. R.G. Cigarroa, R.A. Lange, R.H. Williams, and L.D. Hillis Dosing of contrast material to prevent contrast nephropathy in patients with renal disease Am J Med 86 1989 649 652
23. W.K. Laskey, C. Jenkins, and F. Selzer et al. Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention J Am Coll Cardiol 50 2007 584 590
24. H.S. Thomsen Guidelines for contrast media from the European Society of Uro-genital Radiology AJR Am J Roentgenol 181 2003 1463 1471
25. K. Thygesen, J.S. Alpert, A.S. Jaffe, M.L. Simoons, B.R. Chaitman, H.D. White the Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction Third universal definition of myocardial infarction Circulation 126 2012 2020 2035
26. M. Leoncini, A. Toso, and M. Maioli et al. Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstream TIrofiban, in cath Lab Downstream Abciximab (CLOTILDA) study Am Heart J 150 2005 401.e9 401.e14
27. A.W. Chan, D.L. Bhatt, and D.P. Chew et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention Circulation 105 2002 691 696
28. C.R. Harper, and T.A. Jacobson Managing dyslipidemia in chronic kidney disease J Am Coll Cardiol 51 2008 2375 2384
29. R. Agarwal Statin induced proteinuria: renal injury or renoprotection? J Am Soc Nephrol 15 2004 2502 2503
30. P.A. McCollough, S. Khambatta, and A. Jazrawi Minimizing the renal toxicity of iodinated contrast Circulation 124 2011 1210 1211
31. A. Liuni, M.C. Luca, T. Gori, and J.D. Parker Rosuvastatin prevents conduit artery endothelial dysfunction induced by ischemia and reperfusion by a cyclooxygenase-2-dependent mechanism J Am Coll Cardiol 55 2010 1002 1006
32. P.M. Ridker, E. Danielson, F.A.H. Fonseca for the JUPITER Study Group Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
33. P.M. Ridker, J. MacFadyen, M. Cressman, and R.J. Glynn Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial J Am Coll Cardiol 55 2010 1266 1273
34. D.G. Vidt, S. Harris, F. McTaggart, M. Ditmarsch, P.T. Sager, and J.M. Sorof Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate Am J Cardiol 97 2006 1602 1606
35. E.R. Bates, W.C. Lau, and D.J. Angiolillo Clopidogrel-drug interactions J Am Coll Cardiol 57 2011 1251 1263
36. G. Marenzi, G. Lauri, and E. Assanelli et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction J Am Coll Cardiol 44 2004 1780 1785
37. A.S. Go, G.M. Chertow, D. Fan, C.E. McCulloch, and C.Y. Hsu Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 2004 1296 1305
38. D.D. Waters, and I. Ku Early statin therapy in acute coronary syndromes. The successful cycle of evidence, guidelines, and implementation J Am Coll Cardiol 54 2009 1434 1437
39. R.P. Morrissey, G.A. Diamond, and S. Kaul Statins in acute coronary syndromes: do the guideline recommendations match the evidence? J Am Coll Cardiol 54 2009 1425 1433
40. G. Patti, C.P. Cannon, and S.A. Murphy et al. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies Circulation 123 2011 1622 1632